In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exubera's Problem: It's Still Just Insulin

Executive Summary

Exubera's shaky start isn't that surprising. Pfizer is new to the large molecule game, Exubera's a first of its kind, and, it seems, injections aren't so much the problem as insulin itself.

Related Content

Oral Molecules In An Injectable World: What Developers Need To Do Now
Blow the Launch -- Doom the Product
Can Oral GLP-1 Be More than Just Convenient?
Inhaled Insulin is Dead. Long Live Inhaled Insulin
Business and Technology Briefs
Insulin Delivery: Still Waiting to Exhale
Taking Aim at Diabetes
Januvia: Defining Primary-Care Success and Risk
Best Laid Plans: Pfizer's Torcetrapib Tanks
Inhaled Insulin: Being First Isn't Necessarily Best


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts